Trans-zeatin suppresses osteoclastogenesis and prevents estrogen deficiency-induced bone loss by modulating Nrf2-mediated redox homeostasis and AKT signaling.
- DOI
- 10.1016/j.bcp.2026.118502
- Published
- 2026 Sep 25
- Container
- Biochemical pharmacology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bcp.2026.118502,
title = {Trans-zeatin suppresses osteoclastogenesis and prevents estrogen deficiency-induced bone loss by modulating Nrf2-mediated redox homeostasis and AKT signaling.},
author = {Xiao Y and Lu Q and Shi M and Liang H and Luo J and Wu Y and Wang L and Nan Y and Wei R and Miao J and Tu Y and Liu Y and Sheng S and Jin H},
year = {2026},
journal = {Biochemical pharmacology},
doi = {10.1016/j.bcp.2026.118502},
url = {https://doi.org/10.1016/j.bcp.2026.118502}
}RIS
TY - JOUR TI - Trans-zeatin suppresses osteoclastogenesis and prevents estrogen deficiency-induced bone loss by modulating Nrf2-mediated redox homeostasis and AKT signaling. AU - Xiao Y AU - Lu Q AU - Shi M AU - Liang H AU - Luo J AU - Wu Y AU - Wang L AU - Nan Y AU - Wei R AU - Miao J AU - Tu Y AU - Liu Y AU - Sheng S AU - Jin H PY - 2026 JO - Biochemical pharmacology DO - 10.1016/j.bcp.2026.118502 UR - https://doi.org/10.1016/j.bcp.2026.118502 ER -
APA
Y, X., Q, L., M, S., H, L., J, L., Y, W., L, W., Y, N., R, W., J, M., Y, T., Y, L., S, S., & H, J. (2026). Trans-zeatin suppresses osteoclastogenesis and prevents estrogen deficiency-induced bone loss by modulating Nrf2-mediated redox homeostasis and AKT signaling.. Biochemical pharmacology. https://doi.org/10.1016/j.bcp.2026.118502
Source records
- pubmed · retrieved 2026-09-26T08:35:10.230Z